Jung C, Brubaker L. The etiology and management of recurrent urinary tract infections in postmenopausal women. Climacteric, 2019. https://doi.org/10.1080/13697137.2018.1551871
Key takeaways
- Recurrent UTIs, overactive bladder, and incontinence after menopause are often symptoms of the same underlying hormonal change, a condition called genitourinary syndrome of menopause (GSM), which is treatable but does not resolve on its own.
- NICE has assessed high-quality evidence showing vaginal oestrogen reduced recurrent UTI risk from 62.8% to 16% compared to placebo: yet most women cycling through antibiotics have never been offered it.
- A specialist menopause assessment, rather than another course of antibiotics, is the right starting point for women experiencing repeated bladder problems after menopause.
If you have been getting recurrent UTIs since perimenopause or menopause, you are not unlucky and you are not imagining it. Urinary tract infections become significantly more common after menopause, and for many women they arrive in clusters: one course of antibiotics, a brief respite, then another infection within weeks. What most women are not told is why this keeps happening, or that there is a hormonal explanation and an evidence-based treatment that addresses the root cause rather than just the latest infection.
This article explains the mechanism behind menopause-related bladder problems, introduces the clinical framework that unifies these symptoms, and sets out what the evidence actually shows about treatment, including a treatment option that NICE has assessed as highly effective but that remains remarkably under-prescribed.
Why menopause increases your risk of UTIs and bladder problems
Oestrogen does not just regulate the menstrual cycle. It maintains the health of the tissues lining the urethra, bladder, and vaginal wall: keeping them thick, elastic, and well-supplied with blood. When oestrogen declines during perimenopause and after menopause, those tissues thin and lose resilience. The urethra shortens. The bladder lining becomes more vulnerable to irritation and infection. The body's natural defences against bacteria weaken.
A review published in Climacteric, the journal of the International Menopause Society, found that recurrent UTI prevalence increases from 19% to 36% in premenopausal women and to 55% after menopause. That is not a small shift. For more than half of postmenopausal women, UTIs become a recurring feature of life rather than an occasional inconvenience.
The British Menopause Society's 2025 Consensus Statement on Genitourinary Syndrome of Menopause confirms that urinary symptoms including frequency, urgency, nocturia, and dysuria are directly linked to oestrogen and androgen decline in the genitourinary tract and that these symptoms are clinically distinct from the kind of isolated infection that might affect a younger woman.
The microbiome connection: why bacteria find it easier to thrive
There is a more specific mechanism at work that helps explain why UTIs cluster so persistently after menopause, and it involves the vaginal microbiome.
In premenopausal women, oestrogen supports the dominance of Lactobacillus bacteria in the vaginal and urethral environment. Lactobacillus produces lactic acid, which keeps the local pH acidic. That acidic environment is hostile to the bacteria that cause UTIs, particularly Escherichia coli (E. coli), which is responsible for the majority of urinary tract infections.
When oestrogen declines, Lactobacillus populations fall and pH rises. The environment becomes less hostile to bacteria that would previously have been unable to establish a foothold and can now colonise the urogenital tract and ascend to the bladder.
A 2022 study in Cell Reports Medicine showed that oestrogen deficiency in postmenopausal women with recurrent UTIs was associated with reduced Lactobacillus dominance and altered microbiome composition, and that oestrogen therapy modified that composition. This explains why women who have never had significant UTI problems before menopause suddenly find themselves having them repeatedly.
The full picture: what is genitourinary syndrome of menopause?
Genitourinary syndrome of menopause (GSM) is the medical term for the cluster of bladder and vaginal symptoms caused by declining oestrogen and androgen levels during and after menopause.
GSM is the internationally accepted clinical framework, endorsed by both the British Menopause Society and the American Urological Association's 2025 guideline, for understanding why bladder and vaginal symptoms occur together after menopause. Where previous terminology focused on individual symptoms in isolation, GSM recognises that recurrent UTIs, vaginal dryness, overactive bladder, and urinary incontinence are expressions of the same underlying hormonal change.
Clinically this means treating each symptom in isolation, for example a course of antibiotics here or a recommendation for pelvic floor exercises there, does not achieve full symptom resolution because the hormonal root cause has not been addressed.
“One of the most important and least-known facts about GSM is that symptoms are progressive. They do not resolve without treatment. The BMS 2025 Consensus Statement is explicit on this point, so it is important to seek specialist assessment rather than waiting to see whether things improve.”
Symptoms: UTIs, overactive bladder, incontinence — how to tell them apart
Because GSM encompasses several distinct but related presentations, it is worth knowing what each looks like.
UTI symptoms
The classic picture is that of a burning or stinging sensation when urinating, an urgent and frequent need to pass urine (often producing very little), urine that looks cloudy or smells stronger than usual, and sometimes discomfort or pressure in the lower abdomen. In older women, UTIs may also present with confusion or general deterioration without the classic urinary symptoms.
Overactive bladder
Overactive bladder symptoms are urgency, frequency, and nocturia (waking at night to urinate) in the absence of infection. The bladder contracts unpredictably, producing a sudden and compelling urge to urinate that can be difficult to override. This is driven by the same tissue changes as recurrent UTIs, but there is no infection so antibiotics will not help.
Stress incontinence and urge incontinence
Bladder leakage is one of the most common but least discussed menopause symptoms. Stress incontinence describes leakage triggered by physical pressure such as coughing, sneezing, laughing, or exercise. It results from weakening of the pelvic floor muscles and urethral sphincter. Urge incontinence describes leakage that accompanies a sudden, overwhelming urge to urinate. Both can occur together (mixed incontinence) and are more common after menopause.
"My urine test keeps coming back negative" — what is really happening
This is one of the most frustrating experiences described by women with menopause-related bladder symptoms.
There are two main explanations.
The first is that not all burning, urgency, and frequency in menopausal women is caused by infection. When urogenital tissues are thinned and irritated by oestrogen deficiency, they can produce symptoms that feel indistinguishable from a UTI with the tissue being inflamed and hypersensitive, but not infected. A urine culture in this situation will come back negative, because there is no bacterial infection to detect.
The second is that some infections are sub-threshold meaning enough bacteria are present to cause symptoms, but not at the concentration that triggers a positive culture result using standard diagnostic criteria. A 2023 UK survey study published in Antibiotics, involving 1,096 women and conducted by researchers from Cardiff University and the UK Health Security Agency, found that menopausal women with recurrent UTIs presented with more complex and varied symptom profiles than premenopausal women, raising questions about whether standard diagnostic criteria, which typically require three specific symptoms, adequately capture presentations in this population.
A negative result therefore does not mean your symptoms have no cause. A specialist assessment that considers the hormonal context is warranted when standard diagnostics are not providing answers.
What actually helps: the evidence for treatment
Vaginal oestrogen: the most important preventive treatment
Vaginal oestrogen is a topical treatment that helps restore vaginal tissue, making it thicker, more elastic and more hydrated. In the context of UTI prevention and bladder symptoms, it also restores the urogenital environment that supports Lactobacillus dominance and acidic pH, directly addressing the mechanism that makes recurrent infections more likely.
The evidence for vaginal oestrogen in preventing recurrent UTIs is among the strongest available for any menopause treatment. NICE has assessed high-quality evidence from a randomised controlled trial showing that vaginal oestrogen cream (estriol 0.5 mg) used for eight months reduced recurrent UTI risk to 16.0% compared to 62.8% in the placebo group. Vaginal oestrogen also outperformed oral antibiotics over a three-month comparison period in that assessment. Critically, the evidence relates specifically to local vaginal application.
A large cohort study published in the American Journal of Obstetrics and Gynecology in 2023, involving 5,638 women with a mean age of 70.4 years, found that vaginal oestrogen reduced mean annual UTI frequency from 3.9 to 1.8 infections, meaning a 51.9% reduction. 31.4% of women experienced no UTIs at all in the twelve months following their first prescription.
Despite the compelling evidence, many women cycling through repeated courses of antibiotics have never been offered local oestrogen. If that describes your experience, a 45-minute consultation with a BMS-trained menopause specialist is the place to address that.
Antibiotics
Antibiotics remain the right treatment for a UTI when infection has been confirmed. Repeated antibiotic courses not only leave the underlying vulnerability intact, but may also increase the risk for antimicrobial resistance over time. Vaginal oestrogen reduces how often infections occur in the first place, making antibiotics a less frequent necessity.
Lifestyle and self-management
Staying well hydrated, urinating after sexual intercourse, and wearing breathable cotton underwear are all reasonable self-management measures. Bladder training, which involves gradually extending the time between urinations, can be helpful for overactive bladder and urgency symptoms. D-mannose, a sugar supplement that may interfere with bacterial adhesion to the bladder wall, is commonly used by women with recurrent UTIs. While some women find it genuinely helpful, the evidence base is less robust than for vaginal oestrogen and it is not currently recommended by NICE as a preventive treatment.
Pelvic floor exercises
Pelvic floor muscle training has good evidence for stress incontinence and some evidence for urge incontinence. It is a worthwhile part of a comprehensive management approach, particularly when bladder leakage is a component of the picture. It works best as an adjunct to hormonal treatment for GSM rather than as a standalone response to hormone-driven symptoms.
These symptoms usually get worse without treatment
Thinning and loss of elasticity in the vulval and vaginal tissues advance over time if the hormonal deficit is not corrected through use of oestrogen. Vaginal oestrogen typically produces noticeable improvement in tissue health within a few weeks, with continued improvement over months of use. The sooner treatment begins, the less tissue change there is to address.
Where to get the right support
For many women, the bladder symptoms of menopause are raised at a GP appointment briefly, investigated with a urine dipstick, and treated with antibiotics if the result is positive. The hormonal context is not explored. Vaginal oestrogen is not offered. So the symptoms continue.
A specialist menopause consultation works differently. A 45-minute appointment with a BMS-trained menopause specialist gives you the time to describe the full picture of what you are experiencing: when symptoms started, how they have changed, what you have tried, and what has and has not helped. Blood test monitoring, including oestradiol levels where relevant, informs the clinical picture. A personalised treatment plan can include vaginal oestrogen as a prescribed treatment, alongside other elements of a comprehensive menopause care plan where appropriate.
Among Voy members, 93% reported improvement in overall quality of life after starting treatment, based on outcome data presented at The Menopause Society 2025. That reflects comprehensive care across the full spectrum of menopause symptoms, not any single intervention. Bladder and urogenital symptoms are part of that picture, and they are taken seriously.
If you have blood in your urine, seek urgent medical assessment. Haematuria is not a symptom to attribute to menopause without investigation: it requires prompt evaluation to rule out other causes.
This content is for informational purposes and does not constitute medical advice. Always consult a healthcare professional.
